+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Relapse of acute myelogenous leukemia during low dose interleukin-2 (IL-2) therapy. Phenotypic evolution associated with strong expression of the IL-2 receptor alpha chain



Relapse of acute myelogenous leukemia during low dose interleukin-2 (IL-2) therapy. Phenotypic evolution associated with strong expression of the IL-2 receptor alpha chain



Cancer 75(7): 1594-1597



Background: Interleukin-2 (IL-2) has produced remissions in patients with solid tumors, predominantly malignant melanoma and renal cell carcinoma. Recently, clinical trials have assessed the therapeutic benefit of this cytokine in acute myelogenous leukemia (AML). However, little is known about the potential of IL-2 to promote the growth of leukemic cells in vivo.

(PDF emailed within 1 workday: $29.90)

Accession: 009326144

Download citation: RISBibTeXText

PMID: 8826915


Related references

Interleukin-11 (IL-11) enhances clonal proliferation of acute myelogenous leukemia cells with strong expression of the IL-11 receptor alpha chain and signal transducing gp130. Leukemia 13(7): 1018-1027, 1999

The interleukin-3 receptor alpha chain is highly expressed on primitive acute myelogenous leukemia cells. Blood 94(10 SUPPL 1 PART 1): 67a, Nov 15, 1999

Clinical importance of interleukin-2 receptor alpha-chain expression in acute leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. Cancer Detection and Prevention 21(3): 273-279, 1997

Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. Cancer Journal From Scientific American 6 Suppl 1: S39-S44, 2000

Clinical importance of interleukin-2 receptor alpha-chain expression in acute leukemia. Cancer Detection & Prevention 21(3): 273-279, 1997

Low dose interleukin-2 following intensification therapy with high dose ARA-C for acute myelogenous leukemia in first complete remission. Blood 84(10 SUPPL 1): 302A, 1994

Total body irradiation in acute myeloid leukemia and chronic myelogenous leukemia: influence of dose and dose-rate on leukemia relapse. International Journal of Radiation Oncology, Biology, Physics 17(3): 547-552, 1989

Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. American Journal of Hematology 83(10): 771-777, 2008

Induction of interleukin-2 receptor alpha chain expression on immature acute myelocytic leukemia cells. Leukemia Research. 18(4): 269-274, 1994

Phenotypic analysis of hairy cell leukemia: "variant" cases express the interleukin-2 receptor beta chain, but not the alpha chain (CD25). Blood 82(2): 528-535, 1993

Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis. Leukemia 21(2): 326-332, 2007

Diagnostic and clinical importance of interleukin 2 receptor alpha chain expression on non t cell acute leukemia cells. British Journal of Haematology 80(3): 317-326, 1992

Effects of interferon alpha ifn on the expression of interleukin il 6 tumor necrosis factor alpha tnf and 2 5 oligoadenylate synthetase 2 5 as in acute myelogenous leukemia. Journal of Interferon Research 11(SUPPL 1): S108, 1991